ZA200300996B - Process for the selection of Hiv-1 subtype C isolates, selected Hiv-1 subtype isolates, their genes and modification and derivatives thereof. - Google Patents
Process for the selection of Hiv-1 subtype C isolates, selected Hiv-1 subtype isolates, their genes and modification and derivatives thereof. Download PDFInfo
- Publication number
- ZA200300996B ZA200300996B ZA200300996A ZA200300996A ZA200300996B ZA 200300996 B ZA200300996 B ZA 200300996B ZA 200300996 A ZA200300996 A ZA 200300996A ZA 200300996 A ZA200300996 A ZA 200300996A ZA 200300996 B ZA200300996 B ZA 200300996B
- Authority
- ZA
- South Africa
- Prior art keywords
- sequence
- set out
- hiv
- subtype
- amino acid
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 35
- 238000012986 modification Methods 0.000 title claims description 30
- 230000004048 modification Effects 0.000 title claims description 29
- 238000000034 method Methods 0.000 title claims description 17
- 230000008569 process Effects 0.000 title claims description 12
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
- 108700004025 env Genes Proteins 0.000 claims description 43
- 241000700605 Viruses Species 0.000 claims description 40
- 108091035707 Consensus sequence Proteins 0.000 claims description 39
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 36
- 239000002773 nucleotide Substances 0.000 claims description 31
- 125000003729 nucleotide group Chemical group 0.000 claims description 31
- 108700004026 gag Genes Proteins 0.000 claims description 29
- 101150030339 env gene Proteins 0.000 claims description 28
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 22
- 229920001184 polypeptide Polymers 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 101150098622 gag gene Proteins 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 238000004113 cell culture Methods 0.000 claims description 9
- 238000011161 development Methods 0.000 claims description 8
- 238000009396 hybridization Methods 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 6
- 108020004705 Codon Proteins 0.000 claims description 5
- 230000005540 biological transmission Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 description 34
- 108700004029 pol Genes Proteins 0.000 description 24
- 230000003612 virological effect Effects 0.000 description 20
- 150000007523 nucleic acids Chemical group 0.000 description 17
- 101150088264 pol gene Proteins 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 102100034349 Integrase Human genes 0.000 description 11
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 11
- 108700010070 Codon Usage Proteins 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 101710205625 Capsid protein p24 Proteins 0.000 description 5
- 101710177166 Phosphoprotein Proteins 0.000 description 5
- 101710149279 Small delta antigen Proteins 0.000 description 5
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 4
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 4
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000005180 public health Effects 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 3
- 229940033330 HIV vaccine Drugs 0.000 description 3
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000002856 computational phylogenetic analysis Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000282322 Panthera Species 0.000 description 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004970 cd4 cell Anatomy 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 101100020619 Arabidopsis thaliana LATE gene Proteins 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 101100273797 Caenorhabditis elegans pct-1 gene Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 101100224481 Dictyostelium discoideum pole gene Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108010039334 HIV Envelope Protein gp120 Proteins 0.000 description 1
- 229940033332 HIV-1 vaccine Drugs 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 101001041669 Oryctolagus cuniculus Corticostatin 1 Proteins 0.000 description 1
- 101150110488 POL2 gene Proteins 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101100408804 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pof2 gene Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 101150044611 pel gene Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36151—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21699500P | 2000-07-07 | 2000-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200300996B true ZA200300996B (en) | 2005-04-05 |
Family
ID=22809247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200300996A ZA200300996B (en) | 2000-07-07 | 2003-02-05 | Process for the selection of Hiv-1 subtype C isolates, selected Hiv-1 subtype isolates, their genes and modification and derivatives thereof. |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20070172930A1 (fr) |
| AU (1) | AU2001273313A1 (fr) |
| WO (1) | WO2002003917A2 (fr) |
| ZA (1) | ZA200300996B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2330202T5 (es) | 2001-09-06 | 2014-01-20 | Alphavax, Inc. | Sistemas vectores basados en replicones de alfavirus |
| WO2004050691A2 (fr) * | 2002-12-04 | 2004-06-17 | University Of Cape Town | Procede de production de particules similivirales du vih-1 gag |
| EP1651666B1 (fr) | 2003-07-11 | 2009-05-27 | Alphavax, Inc. | Vaccins contre cytomegalovirus a base d alphavirus |
| AU2005245956B2 (en) | 2004-05-18 | 2011-05-19 | Alphavax, Inc. | TC-83-derived alphavirus vectors, particles and methods |
| CN101072585A (zh) * | 2004-11-01 | 2007-11-14 | 诺华疫苗和诊断公司 | 产生免疫应答的组合方法 |
| US7850977B2 (en) | 2007-06-21 | 2010-12-14 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US6146874A (en) * | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
-
2001
- 2001-07-09 WO PCT/US2001/021701 patent/WO2002003917A2/fr active Application Filing
- 2001-07-09 AU AU2001273313A patent/AU2001273313A1/en not_active Abandoned
-
2003
- 2003-02-05 ZA ZA200300996A patent/ZA200300996B/en unknown
-
2007
- 2007-03-15 US US11/724,551 patent/US20070172930A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002003917A2 (fr) | 2002-01-17 |
| AU2001273313A1 (en) | 2002-01-21 |
| US20070172930A1 (en) | 2007-07-26 |
| WO2002003917A3 (fr) | 2002-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11612649B2 (en) | HIV pre-immunization and immunotherapy | |
| US12090200B2 (en) | Methods of producing cells resistant to HIV infection | |
| De Vreese et al. | The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication | |
| Williamson et al. | Characterization and selection of HIV-1 subtype C isolates for use in vaccine development | |
| US20070172930A1 (en) | process for the selection of HIV-1 subtype C isolates, selected HIV-1 subtype isolates, their genes and modifications and derivatives thereof | |
| Eda et al. | Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection | |
| Gorelick et al. | Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost | |
| LEGRAND et al. | Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients | |
| US7713530B2 (en) | HIV-1 subtype isolate regulatory/accessory genes, and modification and derivatives thereof | |
| Kim et al. | Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01. AE) HIV type 1 | |
| Naylor et al. | Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine—HGP-30-KLH | |
| Schreiber et al. | Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum | |
| Kumar et al. | Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency virus (SHIV89. 6P) | |
| EP1309617B1 (fr) | Procede de selection d'isolats de sous-type c du vih-1, isolats de sous-type c du vih-1 selectionnes, genes, modifications et derives | |
| Ellenberger et al. | Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms | |
| Mooij et al. | Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy | |
| US7910716B2 (en) | Nucleic acids encoding modified South African HIV-1 subtype C gag proteins | |
| WAKRIM et al. | Superinfection of HIV-2-preinfected macaques after rectal exposure to a primary isolate of SIVmac251 | |
| US20130164316A1 (en) | Genetic signatures in hiv-1 subtype c envelope glycoproteins | |
| Avidan et al. | Effect of non-H-2-linked genes on anti-virus immune responses and long-term survival in mice persistently infected with E-55+ murine leukemia virus | |
| WO2010009465A2 (fr) | Vecteur de htlv-ii, et procédés d'utilisation | |
| US11684666B2 (en) | Recombinant HIV compositions and uses thereof in animal models | |
| US20040116660A1 (en) | Process for the selection of hiv-1 subtype c Isolates, selected hiv-1 subtype c isolates, their genes and modifications and derivatives thereof | |
| Fomsgaard et al. | Full-length characterization of A1/D intersubtype recombinant genomes from a therapy-induced HIV type 1 controller during acute infection and his noncontrolling partner | |
| Protection | Vaccination of Rhesus Macaques with |